Company Overview of Dermira, Inc.
Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is i...
275 Middlefield Road
Menlo Park, CA 94025
Founded in 2010
Key Executives for Dermira, Inc.
Co-Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $500.0K
Co-Founder, Chief Medical Officer and Director
Total Annual Compensation: $360.8K
Co-Founder and Senior Vice President of Corporate Development & Strategy
Total Annual Compensation: $284.9K
Chief Financial Officer and Chief Operating Officer
Total Annual Compensation: $367.4K
Chief Development Officer
Total Annual Compensation: $358.7K
Compensation as of Fiscal Year 2016.
Dermira, Inc. Key Developments
Dermira, Inc. Appoints Ian Clements as Vice President, Investor Relations
Jun 6 17
Dermira, Inc. announced the addition of Ian Clements, Ph.D., to the company's leadership team as vice president, investor relations. Dr. Clements brings over 20 years of industry experience to Dermira. Most recently, he led investor relations and corporate communications at Tobira Therapeutics, Inc., which was acquired by Allergan plc. Previously, he led investor relations and corporate communications at Avanir Pharmaceuticals, Inc., until its acquisition by Otsuka Pharmaceutical Co. Ltd. Dr. Clements also held positions at Sequenom, Inc., the Trout Group LLC, an investor relations agency, and Accelrys, Inc.
Dermira, Inc. Presents at Jefferies 2017 Global Healthcare Conference, Jun-06-2017 11:00 AM
May 30 17
Dermira, Inc. Presents at Jefferies 2017 Global Healthcare Conference, Jun-06-2017 11:00 AM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: Andrew L. Guggenhime, Chief Financial Officer and Chief Operating Officer.
Dermira Mulls Acquisitions
May 9 17
Dermira, Inc. (NasdaqGS:DERM) is seeking acquisitions. Dermira has completed a fixed-income offering in the amount of $250 million. Dermira intends to use the net proceeds that it receives from the note offering for working capital, capital expenditures and other general corporate purposes. Dermira may also use a portion of the net proceeds from the offering to expand its business by in-licensing or acquiring, as the case may be, product candidates, technologies, compounds, other assets, commercial products or complementary businesses; however, Dermira has no current commitments or obligations to do so.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|